SNDX Syndax Pharmaceuticals Inc

Just another day bashing $SNDX management for not exiting via M&A when the opportunity presented itself. M&A exit is a strategy that has historically maximizes shareholder value versus GIA 100% of the time (in oncology, 92% of the time in non-oncology). Hopefully the IPF data is good. We've waited this long so why not a few more months. SNDX is down 14% year to date while the $XBI is up 32.7%. We are unaware of any peer commercial-stage oncology focused bio (or non-oncology for that matter) that trades at a lower multiple of analyst consensus revenue estimates with gross margins north of 90%, with only 1 exception $ARDX We hope SNDX considers shareholders above all else as well as patients who can only benefit via scale to help control costs via $INCY acquisition. Don't worry about SNDX's CEO. Simple analysis proves he does better via annual share grants in spite of share price declines (read our 3/31/26 post). This is not investment advice. $IBB

H.C. Wainwright reiterated $SNDX Buy; PT $38 $KURA $ABBV - RHHBY OTSKY BMY INCY AVLN SNY H.C. Wainwright said in its note: Ahead of 3Q earnings, we completed a deeper diligence effort around NPM1m AML biology and market dynamics that provides a granular understanding of the unique headwinds and underappreciated opportunities within R/R NPM1m AML. Our work centered on revisiting commercial assumptions for the NPM1m AML market as compared to KMT2Ar. We spoke to leading hematologist-oncologists to gain a quick perspective on how targeted therapies like Revuforj are being integrated into existing treatment algorithms, and how those protocols diverge between different genetic subsets of AML in both the frontline and R/R setting. Overall, we came away with a nuanced view of the NPM1m market where frequent actionable co-mutations create headwinds from established targeted therapies in treatment sequencing, rather than from menin inhibitors.

$SNDX market cap, analyst consensus revenue estimates & related multiples v $SRRK whose first therapy was approved by the FDA last week. It is interesting to note analysts expect SRRK's therapies to generate roughly 10% more revenues than SNDX for the years FY29 - FY35 yet SRRK trades at a 4X higher market cap? Related revenue multiples are also provided. This is not investment advice but simple analytics suggest either SNDX is undervalued or SRRK is overvalued. We c/b wrong so we're genuinely curious if any SNDX or SRRK investor reads the attachments otherwise Don't worry about SNDX's CEO because he will likely get another generous share grant come this February just like the last few years. Revisit our post from last March where we documented how he takes home more in spite of meaningful drops in share price. Why create synergy & scale to best control costs for these cancer patients by selling to $INCY when one can make so much money GIA in spite of a falling share price? ​$XBI $IBB

$SNDX Sorry to go on a long diatribe-and many here won't understand where I'm coming from. But IMO the debt deal $SNDX did was a very bad call. Having watched it trade-You can clearly see how the stocks trading changed once conversations started w bankers around the deal. How it's correlation to XBI stopped- how the short position dropped 5mm shares on 5/31 reflected the deal closing and then capping stock near exercise price. IMO $SNDX should not have taken GIA strategy. Look to previous posts to further understand. They should have pursued acquisition; but mgmt. preferred being granted RSU's-salary etc. and issued debt to pursue buildout. Were they just naive w debt deal and what comes with it? Trusting the underwriters? Or they didn't care? Trimmed a bunch higher and will buy back if there is a reason-like revenue numbers backing up the talk. Meanwhile $KURA CEO actively buying $2.5M stock in the open market-with more to come Plz. bring on the criticism.. Thx.

$SNDX painful, soon trading at Kura's valuation (own half of its menin inhib, and some pipeline), vs SNDX owning Revu and half of Nikt...

$SNDX waiting for my own comeback – Topline data expected in 4Q26 from Phase 2 trials of axatilimab in IPF and frontline cGVHD –

$SNDX I am trapped in this crap just because I believe ins scarcity but the management is dogshit

$SNDX | Snapshot 📊⚡ • Business: Syndax Pharmaceuticals is a commercial-stage biotech advancing targeted therapies for blood cancers and immune-mediated diseases. • Commercial Assets: Commercializing Revuforj (menin inhibitor for acute leukemia) and Niktimvo (anti-CSF-1R antibody for chronic GVHD). • Bias & Conviction: Bullish Trendline Reversal | Moderate-High Conviction (Bouncing off primary trendline support at $18.15 with back-to-back Jan 2027 bullish LEAP call sweeps). 🎯 Key Levels: 🐂 Bull Trigger: $19.14 🚀 Targets: $22.17 / $25.00 / $25.50 🛡️ Support: $18.15 / $18.00 ⚠️ Risk: $17.50 / $16.50 🔥 Volume & Flow: • 🟢 Repeated institutional call buying in Jan 2027 $22 and $24 Calls at/above ask ($110.7K+ total premium). #SNDX #stocks #finance #hovdid

$SNDX options are always funky on this one. I could sell and I did, some 25c’s for this month at 20 but couldn’t sell out of the 20c’s I bought a while back for 75 🤔

$SNDX lots of 20 P’s still sitting there. Let’s see if they want those in the money come Friday.

$SNDX ruthless, buying slowly on the way down. OPEX has a lot of 20 P’s sitting there; hoping we get back to those by Friday.